This competing renewal application represents the merger of two of the most productive nodes of the NIDA Clinical Trials Network - the New England Node, led by Yale University's Kathleen Carroll, Ph.D., and the Northern New England Node, led by Harvard University's Roger Weiss, M.D.- to form the New England Consortium Node (NECN). Drs. Carroll and Weiss will both be PIs of the NECN, using the multiple PI mechanism. This proposal to combine these two nodes enhances the strengths of each node by providing broader and deeper scientific expertise and greater diversity of community treatment programs (CTPs). Beyond capitalizing on economies of scale for prudent use of CTN resources, our nodes provide an ideal opportunity for integration, based on 1) geographical proximity, 2) complementary scientific expertise, 3) a history of collaboration, and 4) complementary CTP patient populations. Since joining the CTN, the New England and Northern NE Nodes have been highly productive in all key areas of CTN performance: 1) trial leadership, 2) scientific productivity, including publications and presentations, 3) administrative leadership, 4) excellent trial performance, and 5) dissemination of findings from CTN trials to CTPs. NECN personnel have led 4 highly successful and productive CTN trials and have been leaders in disseminating findings of CTN-tested interventions to the wider drug abuse treatment community, both in New England and nationally. Administrative leadership is exemplified by election by our CTN peers to virtually all major CTN leadership positions. NECN CTPs have adopted a number of evidence- based practices, and have themselves disseminated information about these practices regionally, nationally, and internationally. This proposal highlights the accomplishments of the New England and Northern NE Nodes in their current funding periods and their entire tenure in the CTN. The proposal also describes plans for integration of these two highly successful nodes into a seamlessly integrated combined node. Finally, the proposal will use a number of potential research ideas that are consistent with the evolving mission of the CTN.
The CTN does clinically relevant drug abuse research in real-world settings;the structure of the CTN is designed to maximize the likelihood that treatments found to be successful in CTN trials are then disseminated widely to CTPs nationally, which should help improve the overall treatment of drug abuse and comorbid conditions nationwide.
|McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531|
|Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951|
|Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032|
|Paris, Manuel; Silva, Michelle; Añez-Nava, Luis et al. (2018) Culturally Adapted, Web-Based Cognitive Behavioral Therapy for Spanish-Speaking Individuals With Substance Use Disorders: A Randomized Clinical Trial. Am J Public Health 108:1535-1542|
|Fitzmaurice, Garrett M; Lipsitz, Stuart R; Weiss, Roger D (2017) Statistical considerations in the choice of endpoint for drug use disorder trials. Drug Alcohol Depend 181:219-222|
|Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80|
|Medlock, Morgan M; Rosmarin, David H; Connery, Hilary S et al. (2017) Religious coping in patients with severe substance use disorders receiving acute inpatient detoxification. Am J Addict 26:744-750|
|Carroll, Kathleen M; Kiluk, Brian D (2017) Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again. Psychol Addict Behav 31:847-861|
|Blanco, Carlos; Campbell, Aimee N; Wall, Melanie M et al. (2017) Toward National Estimates of Effectiveness of Treatment for Substance Use. J Clin Psychiatry 78:e64-e70|
|Worley, Matthew J; Heinzerling, Keith G; Shoptaw, Steven et al. (2017) Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. Addiction 112:1202-1209|
Showing the most recent 10 out of 135 publications